As a result of conducted researches the authors have found that MIGU-4 has high tissue availability, quickly penetrates through blood-brain barrier. The half-elimination period is 17 hours; MRT — 25 hours. The brain is referred to the central part of the kinetic distribution scheme. Pharmacokinetic indices of MIGU-4 testify to hopeful outlook of the complex concerning its subsequent studying and clinical use.
